February 3-4, 2015 – Philadelphia, PA
CBI invites you to join your colleagues this February at CBI’s Expanded Access Programs, a tailored, two-day meeting for those considering or currently working on the design and execution of a variety of access management programs, including but not limited to: Expanded Access Programs, Early Access Programs, Compassionate Use Programs, Named Patient Programs and Managed Access Programs.
As the issues around early access, compassionate use and patient voice in R&D grow in prominence and importance within the FDA and the patient community, now is the time to prepare your organization to ensure the ethical and compliant delivery of Early Access Programs. https://www.cbinet.com/conference/PC15193 Share best practices and lessons learned regarding providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes.
Gain critical insight on pressing issues from a dynamic group of key stakeholders from companies including Boston Biomedical Pharma, Genzyme, Pfizer, Bristol-Myers Squibb, Novartis Oncology, Raptor Pharmaceuticals, and more!
Special highlights include:
- FDA Address: New Models for Patient Collaborations and Key Standards for Programs and Protocols
- NORD Address: Paving the Path for Expanded Access to Investigational Drugs — U.S. Considerations from a Patient and Policy Perspective
- BIO Address: Policy, Science and Compassion — Company Commitment, Challenges and Considerations for Access to Unapproved Product
- Point Counterpoint Drug Debate: Take Pause vs. Too Urgent to Wait
*Offer valid through February 3, 2015, applies to standard rates only and may not be combined with other offers, category rates, promotions or applied to a current registration.